To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects

Summary

This is a Phase I study that randomized, double-blind, Placebo-controlled, Parallel Group, Single Ascending Dose Study to evaluate Safety, Tolerability and Pharmacokinetics of CT-P63 in Healthy Subjects.

Timeline

Start

2021-10-11

Primary completion

2021-11-12

Completion

2022-01-25

Outcome

Met primary endpoint

release “The study met its primary objectives with data showing CT-P63 to be safe and well tolerated” celltrion.com ↗

Drugs

Indications